Pegylated Recombinant Human Arginase I

BIOLOGICAL2 trials

Sponsors

Bio-Cancer Treatment International Limited

Conditions

Hepatocellular CarcinomaNeoplasm

Phase 1

Study of Pegylated Human Recombinant Arginase for Liver Cancer

CompletedNCT00988195

Bio-Cancer Treatment International LimitedHepatocellular Carcinoma, Neoplasm

Start: 2008-05-31End: 2009-08-31Updated: 2012-03-14

Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)

CompletedNCT01092091

Bio-Cancer Treatment International LimitedHepatocellular Carcinoma, Neoplasm

Start: 2010-03-31End: 2012-02-29Updated: 2012-03-14

Related Papers

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.

2021-04-1534 citations

Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics, and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.

Journal of Clinical Oncology2014-05-203 citations